Mosaic Biosciences in the News

October 30, 2024 - Mosaic Biosciences Expands Executive Leadership Team

Luyuan Mendhi, Tracey Mullen, and Christilyn Graff Add Deep Industry Knowledge and Leadership Strength to Mosaic's Executive Team

Read More
April 2, 2024 - Expansion of Leading Drug Discovery and Development Expertise

Malavi Madireddi and Scott Glaser Bring Additional Deep Knowledge and Experience to Senior Leadership Team

Read More
June 14, 2022 - Financing to Support Commercial Growth

Mosaic Biosciences Secures Financing from Telegraph Hill Partners to Support Commercial Growth and Expand Drug Discovery Capabilities and Services

Read More
May 2, 2022 - Scientific Partnership

Ingenia Therapeutics and Mosaic Biosciences Present Preclinical Data on the Variants of the Bispecific Antibody IGT-427 for the Treatment of Degenerative Retinal Diseases

Read More
June 29, 2021 - Developing Partnership

Ocular Therapeutix™ and Mosaic Biosciences Enter into Strategic Discovery Collaboration Targeting the Treatment of Dry Age-Related Macular Degeneration

Read More
December 19, 2019 - Developing Partnership

Catalyst Biosciences Announces Global License and Collaboration Agreement to Develop Pegylated CB2892 for the Treatment of Dry Age-Related Macular Degeneration

Read More
August 29, 2019 - Scientific Presentation

Catalyst Biosciences and Mosaic Biosciences Present Preclinical Data on Pegylated CB2782 for the Treatment of Dry Age-Related Macular Degeneration

Read More
October 24, 2017 - Developing Partnership

Catalyst Biosciences and Mosaic Biosciences Enter into Strategic Collaboration to Develop Intravitreal Anti-Complement Factor 3 (C3) Products for the Treatment of Dry AMD and Other Retinal Diseases

Read More